Comments
Description
Transcript
nab-Paclitaxel
nab-paclitaxel in monoterapia Dati clinici e safety nab-paclitaxel in monoterapia Studi clinici che hanno portato all’indicazione Gli studi pre-registrativi nell’ MBC Phase I1 Dose-finding study • No steroid premedication • DLTs at 375 mg/m2: keratitis, neuropathy-sensory, stomatitis • MTD: 300 mg/m2 • Linear PK Phase II2 175 mg/m2 Phase II3 300 mg/m2 • ORR 40% • First-line response 45% • Well tolerated without steroids • 0% grade 3/4 neuropathy • ORR 48% • First-line response 64% • Well tolerated without steroids • 11% grade 3/4 neuropathy Pivotal phase III study (n = 460)4 260 mg/m2 NAB-P vs 175 mg/m2 paclitaxel 1. Ibrahim et al. Clin Cancer Res. 2002;8:1038–1044 2. American BioScience, Inc. Data on File 3.Ibrahim et al. J Clin Oncol. 2005;23:6019–6026 4. Gradishar et al. J Clin Oncol. 2005;23:7794–7803 Studi di Fase 1 • Phase I –MTD, PK, etc. • Phase II • Phase III –Registration RCT –Other Studio fase I “DOSE FINDING” • No premedicazione steroidea • No reazioni acute di ipersensibilità • Tossicità Dose-limitanti da taxano a 375 mg/m2 (neuropatia, cheratite, stomatite) • Dose Massima Tollerata: 300 mg/m2 • Durata infusione tollerabile: 30 minuti • AUCs lineari nel range di dose clinicamente rilevante Phase I and Pharmacokinetic Study of ABI007, a cremophore-free, protein-stabilized, nanoparticle formulation of paclitaxel A new paradigm in cancer therapy: the nabTM platform • Receptor-mediated transport (via gp60) and specific protein (SPARC) binding in tumour with the goal of improving efficacy and the therapeutic index • Phase I studies were conducted to determine the safety, MTD and PK profile of this novel formulation 140 80 NAB-P Paclitaxel 60 40 20 0 0 20 40 60 80 100 Dose (mg/kg) 50% higher paclitaxel dose Paclitaxel (nCi/g) Mortality (%) 100 120 NAB-P (20 mg/kg) Paclitaxel (20 mg/kg) 100 80 60 40 0.01 0.1 1 10 100 Hrs 33% higher intra-tumour paclitaxel Ibrahim et al. Clin Cancer Res. 2002:8;1038–1044 NAB-P was administered safely over 30 minu with no HSR • 19 patients treated • No HSRs observed during the infusion period • Haematological toxicity (characterised by ANC and PLT nadirs) mild and dosedependent • DLTs (in three of six patients treated at dose level 3): sensory neuropathy (n = 3), stomatitis (n = 2) and superficial keratopathy (n = 2) • MTD defined as 300 mg/m2 ANC nadir x 103/mm3 (range) PLT nadir x 103/mm3 (range) 0 2.229 (1.850–5.040) 204 (174–292) 1 1.845 (0.586–3.729) 197 (118–270) 2 0.960 (0.264–3.680) 200 (105–609) 3 0.966 (0.018–1.804) 173 (25–251) Dose level ANC, absolute neutrophil count; DLT, dose-limiting toxicity; HSR, hypersensitivity reaction; PLT, platelet Ibrahim et al. Clin Cancer Res. 2002:8;1038–1044 Paclitaxel PK for nab-Paclitaxel are Linear Paclitaxel nab-Paclitaxel Paclitaxel AUC 3 hr1 Mean AUCinf (ng hr/ml) 45 000 Paclitaxel AUC 3 hr2 35 000 Paclitaxel AUC 1 hr3 30 000 y = 3213e0.0095x 40 000 R2 = 0.9328 35 000 y = 3023.2e0.0089x 30 000 R2 = 0.9683 25 000 20 000 15 000 25 000 20 000 15 000 10 000 5000 10 000 0 5000 0 100 AUCinf (ng hr/mL) 50 000 nab-Paclitaxel4 N= 3 6 150 200 Dose (mg/m2) 250 300 51 3 3 12 5 4 75 100 125 150 175 200 225 250 275 300 325 350 375 nab-Paclitaxel dose (mg/m2) 1Kearns. Pharmacotherapy. 1997;17:105S–109S 2Taxol package insert 3Ross et al. Cancer Chemother Pharm. 2000 4nab-paclitaxel® NDA Studi di fase II • Phase I –MTD, PK, etc. • Phase II • Phase III –Registration RCT –Other • nab-paclitaxel 300mg/m2 q 3w • MBC w measurable disease • No taxanes within past 6 months nab-Paclitaxel Phase II Trial: Purpose • To evaluate the safety and antitumor activity of nabPaclitaxel in MBC patients • Treatment Regimen – nab-paclitaxel 300 mg/m2 q3w, no standard pre-medication • Primary endpoint – tumor response rate (CR or PR) • Secondary endpoints – – – – TTP OS Antitumor activity in anthracycline-naïve vs. anthracycline-exposed patients Changes in quality of life from baseline Ibrahim NK et al. J Clin Oncol. 2005; 23: 6019−6026 Metodi Statistici • Endpoint primario di efficacia basato su popolazione ITT • Criteri Successo / Fallimento – 30% tasso di risposta (ORR) per nab-paclitaxel in pazienti pre-trattati con anthracycline • Tutti i pazienti che ricevevano una dose erano inclusi in analisi di risposta e tossicità nab-paclitaxel Trial Fase II Pazienti • N = 63 pazienti con malattia misurabile CMM • Precedente Taxano > 6 mesi Caratteristiche – Lesioni Metastatiche > 3 – Polmone / Fegato – 1a Linea di Terapia per CMM – Naïve Chemoterapia – Precedente Anthraciclina – Precedente Taxano 41% 57% 62% 24% 59% 17% Ibrahim NK et al. J Clin Oncol. 2005; 23: 6019−6026 nab-paclitaxel Trial Fase II Risultati primari • ORR = 48% • WHO = criteri RECIST • 1a Linea = 64% • Pretrattate con antracicline = 41% • 3a Linea = 22% Risultati secondari • TTP = 26.6 settimane • Responders = 48.1 settimane • OS = 63.6 settimane Ibrahim NK et al. J Clin Oncol. 2005; 23: 6019−6026 Treatment-related toxicities Treatment-related grade 3 and 4 toxicities/AEs (N = 63) Grade 3 Grade 4 Haematological toxicities No. (%) No. (%) Neutropaenia† 17 (27) 15 (24) Leucopoenia 12 (19) 3 (5) Infection with unknown absolute neutrophil count 4 (6) 0 (0) Febrile neutropaenia 0 (0) 3 (5) Anaemia 3 (5) 1 (2) Thrombocytopenia 3 (5) 0 (0) †N = 62 Note: if a patient reported the same toxicity more than once, that patient was only counted once for the summary of that toxicity, using the most severe intensity. Haematological toxicities were based on laboratory values; others were based on AE reports from the clinical investigators Ibrahim NK et al. J Clin Oncol. 2005; 23: 6019−6026 Treatment-related toxicities (cont.) Treatment-related grade 3 and 4 toxicities/AEs (N = 63) Grade 3 Grade 4 No. (%) No. (%) Fatigue 8 (13) 0 (0) Sensory neuropathy 7 (11) 0 (0) Myalgia 5 (8) 0 (0) Diarrhoea 3 (5) 0 (0) Cardiac - ischaemia/infarction 0 (0) 1 (2) Jaundice 0 (0) 1 (2) Vomiting 1 (2) 0 (0) Nausea 1 (2) 0 (0) Headache 1 (2) 0 (0) Mucositis 1 (2) 0 (0) Rash/desquamation 1 (2) 0 (0) Stomatitis/pharyngitis 1 (2) 0 (0) Non-haematological toxicities Ibrahim NK et al. J Clin Oncol. 2005; 23: 6019−6026 Treatment-related toxicities Percentage of patients 100 90 Grade 1 80 Grade 2 70 60 50 Grade 3 Grade 4 40 30 20 10 0 Ibrahim NK et al. J Clin Oncol. 2005; 23: 6019−6026 Treatment-Related Toxicities • Grade 4 neutropeenia – Primarily during the first treatment cycle and managed with dose reductions • Grade 3 neuropathy – All occurrences were sensory neuropathy – Five patients discontinued due to neuropathy (8%) • Myalgia – Episodes were worse immediately after dosing and resolved by next dose (no discontinuation) • Ocular/visual – Mostly dry eye and blurred vision (no G3) Ibrahim NK et al. J Clin Oncol. 2005; 23: 6019−6026 Conclusioni • NAB-P demonstrated significant antitumour activity and a favourable safety profile in patients with MBC • No premedication, prolonged infusions or special IV infusion sets are required with NAB-P • The significant antitumour activity and favourable safety profile of NAB-P may be related to both • exploitation of albumin to obtain high intratumoral concentration via gp60 and SPARC • the absence of polyethylated castor oil • The low incidence of neutropaenia makes NAB-P a good candidate for combination treatment regimens Ibrahim NK et al. J Clin Oncol. 2005; 23: 6019−6026 Conclusioni: Review Punti principali: • Popolazione Eterogenea 63 pazienti con CMM: (1a - 3a Linea), (Precedentemente trattati con/senza Anthracicline) • ORR = 48%: (1a Linea = 64%), (Antrac. = 41%) • Effetti collaterali: (Grado 4 Neutropenia = 24%), (NF = 5%), (Grado 3 Neuropatia = 11%) Ibrahim NK et al. J Clin Oncol. 2005; 23: 6019−6026 Studi di Fase III • Phase I • MTD, PK, etc. • Phase II • Phase III –Registration RCT –Other CA-O12: nab-paclitaxel Trial Pivotal Fase III Phase III Trial of Nanoparticle Albumin-bound Paclitaxel Compared with Polyethylated Castor Oilbased Paclitaxel in Women with Breast Cancer William J. Gradishar, Sergei Tjulandin, Neville Davidson, Heather Shaw, Neil Desai, Paul Bhar, Michael Hawkins, and Joyce O’Shaughnessy Gradishar et al. J Clin Oncol 23: 7794-7803. Nov 2005. Phase III Trial of nab-Paclitaxel Compared with Polyethylated Castor Oil-Based Paclitaxel in Women with Breast Cancer NAB-P 260 mg/m2 iv over 30 min q3w No standard premedication Randomisation (1:1) n = 460 Paclitaxel 175 mg/m2 iv over 3 hrs q3w Standard premedication with dexamethasone and antihistamines Gradishar et al. J Clin Oncol. 2005;23:7794–7803 Fase III: obiettivi Goals: Confrontare l’attività antitumorale di nab-paclitaxel e paclitaxel convenzionale in pazienti con carcinoma mammario metastatico. Valutare la safety e tollerabilità di nab-paclitaxel confrontata al paclitaxel convenzionale. Endpoints Primari Objective response rates (ORR) Tutti I pazienti trattati & 1° linea (analisi pianificata) RECIST criteria Safety e tollerabilità Endpoints Secondari Time to tumour progression (TTP) Overall survival (OS) Gradishar et al. J Clin Oncol. 2005;23:7794–7803 Phase III: inclusion criteria • Females ≥ 18 yrs of age • Measurable MBC • ECOG PS 1 or 2 • Patients stratified for prior anthracycline exposure • No prior taxane for metastatic disease • No limit on number of prior therapies in the metastatic setting Gradishar et al. J Clin Oncol. 2005;23:7794–7803 Select Baseline Characteristics: Primary Site of Measurable Disease nab-Paclitaxel n=229 Paclitaxel n=225 53 53 Liver 40% 43% Lung 32% 35% LN, soft tissue only 16% 13% Abdominal 4% 3% Bone involvement 6% 6% Unknown 1% 0% Mean Age (yr) Gradishar et al. J Clin Oncol 23: 7794-7803. Nov 2005. Demographics: Terapie precedenti nab-Paclitaxel n=229 Paclitaxel n=225 Anthracycline-adiuvante e/o metastatico 77% 78% Anthracycline per malattia metastatica 50% 58% Precedente CT per malattia metastatica: Nessuna 1 regime 2 regimi >2 regimi 42% 41% 10% 7% 40% 43% 16% 2% Gradishar et al. J Clin Oncol 23: 7794-7803. Nov 2005. Overall Response Rate (RECIST) Tutti i pazienti Pazienti 1a linea nab-paclitaxel Standard paclitaxel nab-paclitaxel Standard paclitaxel (N = 229) (N = 225) (N = 97) (N = 89) CR+PR 33% 19% 42% 27% 95% CI 27-39% 14-24% 32-52% 18-36% P-value* †Cochran-Mantel-Haenszel P = 0.001 P = 0.029 test CR, complete response PR, partial response Gradishar WJ et al. J Clin Oncol 2005;23: 7794-7803 Phase III: NAB-P improved ORR independent of line of therapy and across various subgroups 60 P = 0.001 P = 0.029 P = 0.006 P = 0.002 P = 0.002 34.1% 33.5% ORR (± 95% CI) 50 42.3% 40 33.2% 30 20 27.0% 26.5% 18.7% 18.3% 18.7% 13.2% 10 0 NAB-P Paclitaxel All patients 229 225 First-line therapy 97 89 > First-line therapy 132 136 Anthracycline exposed 176 175 Visceral disease 176 182 Greater ORR was confirmed by an independent review committee Gradishar et al. J Clin Oncol. 2005;23:7794–7803 Phase III: NAB-P was associated with increased paclitaxel intensity and improved outcome • Cross trial comparison (consistent with phase III data) CALGB 93421 (n = 474) q3w regimen (mg/m2) Pivotal phase III trial2 (n = 454) Paclitaxel 175 Paclitaxel 210 Paclitaxel 250 NAB-P 260 Paclitaxel 175 23 26 21 33 19 P = 0.001 3.9 mo (16.8 wks)† 4.1 mo (17.6 wks)† 4.9 mo (21.1 wks)† P = 0.045 23.0 wks 16.9 wks P = 0.006 Neutropaenia grade 4 (%) 34 44 53 9 22 P ≤ 0.001 Neuropathy grade 3 (%) 7 19 32 10 2 P ≤ 0.001 ORR (%) TTP †Wks = mo x 4.3 Cancer and leukaemia group B 9342 data with paclitaxel may not reflect on the active ingredient per se, but rather on the increased concentrations of Cremophor® EL implicated in drug entrapment in micelles and added toxicities 1. Winer et al. J Clin Oncol. 2004;22:2061–2068 2. Gradishar et al. J Clin Oncol. 2005;23:7794–7803 Fase III: nab-paclitaxel prolungato “time to disease progression” in tutti i pazienti • Median TTP was significantly longer with NAB-P vs. solvent-based paclitaxel for all patients (23.0 vs. 16.6 weeks; HR = 0.726; P = 0.002) 1.00 NAB-P (n = 229) Proportion not progressed Paclitaxel (n = 224) P = 0.006 HR = 0.75 0.75 Median = 23.0 wks (19.4–26.1) 0.50 0.25 Median = 16.9 wks (15.1–20.9) 0.00 0 8 16 24 32 40 48 56 64 72 80 88 96 104 112 120 Wk Note: P value from log-rank test Gradishar et al. J Clin Oncol. 2005;23:7794–7803 Phase III: OS in tutti i pazienti • All patients treated with NAB-P showed a trend for greater median OS vs. solvent-based paclitaxel (65 vs. 55.7 weeks; P=0.374) 1.00 NAB-P (n = 229) Paclitaxel (n = 225) Probability of survival 0.75 Median = 65.0 wks (52.1–76.9) P = 0.374 HR = 0.90 0.50 Median = 55.7 wks (48.0–66.4) 0.25 0.00 0 8 16 24 32 40 48 56 64 72 80 88 96 104112 120 128 136 144 Wk Note: P value from log-rank test Gradishar et al. J Clin Oncol. 2005;23:7794–7803 Phase III: NAB-P significantly prolonged OS in > first-line patients • NAB-P significantly prolonged median OS in patients receiving > first-line therapy vs. solvent-based paclitaxel (56.4 vs 46.7 weeks; HR=0.73; P=0.024) 1.00 NAB-P (n = 131) Probability of survival Paclitaxel (n = 136) 0.75 Median = 56.4 wks (45.1–76.9) P = 0.024 HR = 0.73 0.50 Median = 46.7 wks (39.0–55.3) 0.25 0.00 0 Note: P value from log-rank test 8 16 24 32 40 48 56 64 72 80 88 96 104 112 120 128 136144 Wk Gradishar et al. J Clin Oncol. 2005;23:7794–7803 Phase III: tossicità ematologiche nab-paclitaxel ben tollerato NAB-P n = 229 Grade AE (%) Neutropaenia Thrombocytopaenia Anaemia Febrile neutropaenia Septic deaths †Cochran-Mantel-Haenszel 3 25 <1 <1 <1 test based upon all grades 4 9 0 <1 <1 0 Paclitaxel n = 225 Grade 3 32 <1 0 <1 4 22 0 <1 0 0 P value† < 0.001 0.290 0.279 0.491 – Gradishar et al. J Clin Oncol. 2005;23:7794–7803 Phase III: NAB-P was associated with increased sensory neuropathy NAB-P n = 229 Grade AE (%) Hypersensitivity Flushing Sensory neuropathy Fatigue Myalgias Vomiting Oedema †Cochran-Mantel-Haenszel Paclitaxel n = 225 Grade 2 <1 <1 3 0 0 4 0 0 2 0 5 3 1 0 4 0 0 P value† 0.150 < 0.001 20 10 0 10 2 0 < 0.001 13 12 4 2 8 7 3 0 <1 0 <1 0 16 15 4 <1 3 2 1 <1 <1 0 0 0 0.062 0.567 0.022 0.851 test based upon all grades Gradishar et al. J Clin Oncol. 2005;23:7794–7803 Phase III: sensory neuropathy following NAB-P 260 mg/m2 q3w improved rapidly + Proportion not resolved 1.00 + NAB-P (n = 24) + 0.75 + 0.50 NAB-P median time to resolution to a lesser grade: 22 days (95% CI: 17–22 days) vs. 79 days with solvent-based paclitaxel 0.25 0.00 0 10 20 30 40 50 60 70 80 90 100 110 120 130 Days since grade 3 to lower grade +Censored Gradishar et al. J Clin Oncol. 2005;23:7794–7803 Fase III: neuropatia migliorata rapidamente nella maggior parte dei pazienti 24 pazienti (10%) con nab-paclitaxel® hanno sviluppato grado 3 neuropatia: • 14 / 24 rapido miglioramento con una mediana di 22 giorni • 71% (10/14) con miglioramento hanno ripreso nab-paclitaxel® ad una dose ridotta • solo 3% (6/233) interrotto nab-paclitaxel® a causa della neuropatia sensoriale • no neuropatia motoria in entrambi I bracci di trattamento Gradishar et al. J Clin Oncol. 2005;23:7794–7803 Phase III: nab-paclitaxel ben tollerato in pazienti ≥ 65 aa • AEs erano simili in pazienti < 65 e ≥ 65 aa in entrambi I gruppi AE (%) Neutropenia Leucopenia Nausea Iperglicemia Flushing NAB-P n = 229 23 10 20 0 0 Paclitaxel n = 225 59 31 38 19 16 NO effetti collaterali addizionali per nab-paclitaxel® in pazienti 65 aa rispetto a pazienti più giovani Gradishar et al. J Clin Oncol. 2005;23:7794–7803 Conclusioni Confronto con solvent-based paclitaxel - nab-paclitaxel® ha dimostrato un significativamente maggiore tasso di risposta e prolungato TTP - nab-paclitaxel® ha prolungato sopravvivenza in pazienti con CMM trattati come seconda linea - L’incidenza di grade 4 neutropenia è stata significativamente più bassa per nab-paclitaxel® - Maggiore tasso di neuropatia sensoriale grade 3 con nab-paclitaxel® ma risolta rapidamente con una mediana di 22 giorni verso 79 giorni per solventbased taxano - no Severe HSRs con nab-paclitaxel® con assenza di premedicazione e più breve tempo di infusione HSR, hypersensitivity reaction Gradishar et al. J Clin Oncol. 2005; 23: 7794–7803 Phase III: Subgroup Analysis Comparing nab-paclitaxel® with Paclitaxel in Patients with MBC Previously Treated with Anthracycline Davidson et al. EBCC. 2008. Poster# 569 Phase III: prior anthracycline patient demographics Metastatic anthracycline (n = 245) Metastatic or adjuvant anthracycline (n = 351) nabpaclitaxel® (n = 115) Paclitaxel (n = 130) nab-paclitaxel® (n = 176) Paclitaxel (n = 175) mean 53.3 53.8 52.6 52.8 range 27–79 34–83 27–79 30–83 white 111 (97) 128 (98) 169 (96) 169 (97) other 4 (3) 2 (2) 7 (4) 6 (3) 109 (95) 127 (98) 165 (94) 172 (98) 2 6 (5) 3 (2) 10 (6) 3 (2) 3 0 (0) 0 (0) 1 (< 1) 0 (0) Age (yrs) Race, n (%) ECOG PS, n (%) ≤1 Davidson et al. EBCC. 2008. Poster# 569 Phase III CA012: nab-paclitaxel significantly improved ORR by 16% over paclitaxel Sub-analysis of anthracycline pretreated patients P = 0.002 nab-paclitaxel Paclitaxel ORR (%) P = 0.01 Davidson et al. EBCC. 2008. Poster# 569 Phase III CA012: nab-paclitaxel had a significantly longer TTP compared with paclitaxel Prior anthracycline in metastatic setting only Prior anthracycline (adjuvant or metastatic setting) 1.00 Proportion not progressed Proportion not progressed 1.00 P = 0.004 0.75 0.50 0.25 P = 0.011 0.75 nab-paclitaxel Paclitaxel 0.50 0.25 0.00 0.00 0 16 32 48 64 Wks 80 96 120 0 16 32 48 64 Wks 80 96 120 Davidson et al. EBCC 2008. Poster #569 Phase III CA012: nab-paclitaxel significantly prolonged OS compared with paclitaxel Prior anthracycline in metastatic setting only B Prior anthracycline (adjuvant or metastatic setting) A 1.00 1.00 P = 0.049 Probability of survival Probability of survival P = 0.049 0.75 0.50 0.25 0.75 nab-paclitaxel Paclitaxel 0.50 0.25 0.00 0.00 0 16 32 48 64 80 96 112 128 Wks 152 0 16 32 48 64 80 96 112 128 Wks 152 Davidson et al. EBCC 2008. Poster #569 CA012: conclusions from subgroup analysis • This subset analysis evaluating patients previously treated with anthracycline shows that, compared with paclitaxel, treatment with nab-paclitaxel® – significantly improved clinical outcomes in patients with MBC • nab-paclitaxel® achieved significantly higher ORRs • nab-paclitaxel® had a significantly longer TTP • nab-paclitaxel® significantly prolonged survival benefit – is effective for the treatment of patients with MBC nab-paclitaxel in monoterapia Altri dati/studi: pazienti pesantemente trattate con taxani November 2007 • nab-paclitaxel 100 or 125mg/m2 qw • MBC w measurable disease • PD on taxanes or relapse within 12 months from adjuvant taxanes nab-Paclitaxel QW Regimen Phase II Trial in Taxane-Refractory MBC: Purpose • To explore whether nab-paclitaxel has antitumor activity in patients with MBC that had progressed on conventional taxane therapy • Primary Endpoint • Percentage of patients who achieved a confirmed objective, complete, or partial response • Secondary Endpoints • • • • SD after > 16 weeks PFS OS Safety Blum et al. Clin Breast Cancer. 2007;7:850–856 nab-Paclitaxel QW Regimen Phase II Trial in Taxane-Refractory MBC: Trial Design • Heavily pre-treated, taxane-refractory patients PATIENT COHORTS nab-Paclitaxel 100 mg/m2 qw 3/4 n = 106 nab-Paclitaxel 125 mg/m2 qw 3/4 n = 75 Study initiated at 100 mg/m2 qw 3 of 4 wks. Because minimal toxicities were observed at this dose and schedule, protocol was amended to include additional cohort of patients to receive 125 mg/m2 qw 3 of 4 wks. Each cohort was analyzed separately. Blum et al. Clin Breast Cancer. 2007;7:850–856 nab-Paclitaxel QW Regimen Phase II Trial in Taxane-Refractory MBC: Select Demographics and Baseline Characteristics Median (range) age, yrs Visceral disease (%) > 3 metastatic sites (%) Tumour progression while on taxane therapy for metastatic disease (%) Previous taxane therapy on a qw schedule for metastatic disease (no. of pts) paclitaxel (%) docetaxel (%) paclitaxel/docetaxel (sequential) (%) Median (range) no. of previous chemotherapy regimens for metastatic disease Previous adjuvant chemotherapy (no. of pts) anthracycline-containing (%) taxane-containing (%) 100 mg/m2 (n=106) 53 (34–76) 94 65 125 mg/m2 (n=75) 53 (33–74) 89 69 88 89 58 41 40 34 26 44 37 20 3 (0–7) 3 (1–14) 85 75 29 79 56 27 Blum et al. Clin Breast Cancer. 2007;7:850–856 nab-Paclitaxel QW Regimen: Responses in Taxane-Refractory MBC n Antitumour activity all patients Prior taxane therapy for metastatic disease Docetaxel Paclitaxel Docetaxel and Paclitaxel †Cochran-Mantel-Haenszel 100 mg/m2 Disease ORR Control (%) (%) n 125 mg/m2 Disease ORR Control (%) (%) 106 14 26 75 16 37 34 30 29 21 13 7 32 30 21 28 20 19 21 20 0 46 45 21 test based upon all grades Blum et al. Clin Breast Cancer. 2007;7:850–856 nab-Paclitaxel QW Regimen: Similar Survival Between Patients Who Achieved SD ≥ 16 wks and Those With a Confirmed Response Probability of survival (%) 100 Survival curves for the 100 and 125 mg/m2 cohorts combined (n = 181) Confirmed responders 75 SD ≥ 16 wks Non-responders 50 25 P = 0.7106 0 0 3 6 9 12 15 18 21 24 27 30 Mo Blum et al. Clin Breast Cancer. 2007;7:850–856 NAB-P qw regimen: safety 100 mg/m2 NCI CTC toxicity/AE 125 mg/m2 Grade 3 Grade 4 Grade 3 Grade 4 19 <1 33 3 14 4 31 3 fatigue 5 0 12 0 sensory neuropathy 8† 0 19† 0 nausea diarrhoea vomiting alopaecia 4 1 3 0 0 0 0 0 3 5 1 0 0 0 0 0 Haematological toxicities (%) leucopaenia neutropaenia (without G-CSF) Non-haematological toxicities (%) †41% of patients treated with NAB-P 100 mg/m2 and 35% of those treated with 125 mg/m2 had pre-existing grade 1 peripheral neuropathy G-CSF, granulocyte-colony stimulating factor NCI CTC, National Cancer Institute common toxicity criteria Blum et al. Clin Breast Cancer. 2007; 7: 850–856 NAB-P qw regimen: peripheral neuropathy improved rapidly • Grade 3 neuropathy • 100 mg/m2 cohort, nine patients (8%) • 125 mg/m2 cohort, 14 patients (19%) • grade 1 pre-existing neuropathy • three patients in 100 mg/m2 and three patients in 125 mg/m2 • Of the 23 patients with grade 3 PN, 15 (65%) restarted NAB-P at a lower dose • patients who continued treatment were able to resume dosing, typically in 1–2 wks PN, peripheral neuropathy Blum et al. Clin Breast Cancer. 2007; 7: 850–856 Conclusions • QW nab-paclitaxel at 100 mg/m2 and 125 mg/m2 achieved – Disease control in 26% and 36% of pts, respectively – PFS of 3.0 mo and 3.5 mo – OS of 9.2 mo and 9.1 mo • There was no significant difference in OS between patients who achieved an objective response and non-responders who had SD ≥ 16 wks • nab-Paclitaxel 100 mg/m2 was well tolerated with no HSR and a low rate of treatment cessation for peripheral neuropathy • Minimal myelosuppression; grade 4 neutropenia and leukopaenia occurred in < 5% of patients in both cohorts Blum et al. Clin Breast Cancer. 2007;7:850–856 nab-paclitaxel in monoterapia Altri dati/studi: confronto verso docetaxel nab-paclitaxel JCO Editorial nab-paclitaxel JCO Editoriale CA-012: nab-paclitaxel vs Taxol TAX 311: Taxotere vs Taxol nab-paclitaxel 260mg/m2 (30min) q 3 wk DOCETAXEL 100mg/m2 (1h) q 3 wk No premedicazione No special tubing R PACLITAXEL 175mg/m2 (3h) q 3 wk Dexametasone 8mg po bid x 5 d Dal giorno precedente all’ infusione R PACLITAXEL 175mg/m2 (3h) q 3 wk Dexametasone 20mg po 12 & 6 h + Dexametasone 20mg po 12 & 6 h + Difenidramine 50mg IV + Difenidramine 50mg IV + Cimetidine 300mg or Ranitidine 50mg IV Cimetidine 300mg or Ranitidine 50mg IV 30-60 min prima dell’ infusione 30-60 min prima dell’ infusione JCO Editorial: CA-012 vs. TAX 311 • Entrambi i trials mostrano avere simili caratteristiche di pazienti e malattia – – – – Simile numero di pazienti in ogni trial Mix di pazienti trattati e non trattati per CMM Precedente trattamento con antracicline Simili Fattori Prognostici • Sia nab-paclitaxel che Taxotere confrontati con Taxol alla dose di 175mg/m2 ogni 3 settimane nab-paclitaxel JCO Editoriale Significantly Longer Progression-Free Survival with nab-Paclitaxel Compared with Docetaxel as First-Line Therapy for Metastatic Breast Cancer W.J. Gradishar, D. Krasnojon, S. Cheporov, A.N. Makhson, G.M. Manikhas, A. Clawson, P. Bhar Gradishar W, et al. J Clin Oncol, 2009; 27(22): 3611-3619. Study Objectives • To obtain comparative safety and preliminary antitumor response data for: – nab-paclitaxel vs docetaxel – weekly (QW) vs every-3-week (Q3W) nab-paclitaxel – lower vs higher dose QW nab-paclitaxel • Design: open-label, randomized, phase II, multi-center study Gradishar W, et al. J Clin Oncol, 2009; 27(22): 3611-3619. qw or q3w NAB-P vs q3w docetaxel: study design • 302 first-line MBC patients randomised to four arms (300 pts received study drug and were evaluable) Comparisons R NAB-P vs docetaxel (A, B, C vs D) A N D qw vs q3w NAB-P (B, C vs A) Arm A: NAB-P 300 mg/m2 q3w Arm B: NAB-P 100 mg/m2 3q4w O M Arm C: NAB-P 150 mg/m2 3q4w I low- vs high-dose qw NAB-P (B vs C) Arms A, C and D administered at the MTD 3q4w, repeated wkly for 3 wks out of 4 S E Arm D: docetaxel 100 mg/m2 q3w Gradishar W, et al. J Clin Oncol, 2009; 27(22): 3611-3619. qw or q3w nab-paclitaxel vs q3w docetaxel: obiettivi dello studio • Ottenere confronto tossicità e dati preliminari di risposta antitumorale per: – nab-paclitaxel® vs docetaxel – qw vs q3w nab-paclitaxel® – lower- vs higher-dose qw nab-paclitaxel® • Utilizzare dati di questo trial per disegnare futuri trials con nab-paclitaxel® Gradishar W, et al. J Clin Oncol, 2009; 27(22): 3611-3619. qw or q3w nab-paclitaxel vs q3w docetaxel: analisi finale - status dello studio nab-paclitaxel® Terapia in corso (%) Interrotta (%) Motivi per interruzione (%) 300 mg/m2 q3w (n = 76) 4 (5) 72 (95) Docetaxel 100 mg/m2 150 mg/m2 100 mg/m2 3q4w 3q4w q3w (n = 76) (n = 74) (n = 76) 6 (8) 14 (19) 3 (4) 70 (92) 60 (81) 71 (96) PD 37 (51) 48 (69) 33 (55) 27 (38) tossicità inaccettabile 10 (14) 5 (7) 10 (17) 15 (21) AEs decisione investigatore 0 7 (10) 1 (1) 5 (7) 2 (3) 6 (10) 2 (3) 14 (20) decisione paziente 18 (25) 11 (16) 8 (13) 13 (18) PD, progressive disease Gradishar W, et al. J Clin Oncol, 2009; 27(22): 3611-3619. qw or q3w nab-paclitaxel vs q3w docetaxel: (RECIST) sperimentatore-ORR 100% 90% 80% B vs D P = 0.002 ORR 70% 50% A vs D NS 40% 46% 60% C vs D P < 0.001 74% 63% 39% 30% 20% 10% 0% 300 mg/m2 q3w (A: n = 76) A vs B; P = 0.024 A vs C; P = 0.002 B vs C; NS NS, not significant 100 mg/m2 3q4w (B: n = 76) 150 mg/m2 3q4w (C: n = 74) Docetaxel 100 mg/m2 q3w (D: n = 74) nab-paclitaxel® Gradishar W, et al. J Clin Oncol, 2009; 27(22): 3611-3619. qw or q3w nab-paclitaxel vs q3w docetaxel: controllo della malattia (ORR + SD > 16 wks) Disease Control Rate: stable disease for 16 weeks or confirmed overall PR or CR P = 0.009 P = 0.017 100 91 % of Patients 90 80 70 83 75 72 68 Independent * Investigator 80 69 58 60 50 40 30 20 10 0 300 mg/m2 q3w A 100 mg/m2 qw 3/4 B nab-Paclitaxel * P-Values 150 mg/m2 qw 3/4 C 100 mg/m2 q3w D Docetaxel for Investigator-assessed DCR are not shown Gradishar W, et al. J Clin Oncol, 2009; 27(22): 3611-3619 qw or q3w nab-paclitaxel vs q3w docetaxel: PFS (Investigator Review) Proportion not progressed 1.00 nab-paclitaxel® 300 mg/m2 q3w (A) Regimen nab-paclitaxel® 100 mg/m2 qw (B) nab-paclitaxel® 150 mg/m2 qw (C) Docetaxel 100 mg/m2 q3w (D) 0.75 0.50 0.25 Median PFS (mo) P value vs docetaxel nab-paclitaxel® (A) 300 mg/m2 q3w 10.9 NS nab-paclitaxel® (B) 100 mg/m2 3q4w 7.5 NS nab-paclitaxel® (C) 150 mg/m2 3q4w (n = 74) 14.6 P = 0.012 HR = 0.568 Docetaxel (D) 100 mg/m2 q3w 7.8 NA 0.00 0 3 6 9 12 15 18 21 24 Mo A vs B; P = 0.076, HR = 0.702 B vs C; P = 0.001; HR = 1.972 Gradishar W, et al. J Clin Oncol, 2009; 27(22): 3611-3619. qw or q3w nab-paclitaxel® vs q3w docetaxel: tossicità† nab-paclitaxel® Docetaxel 300 mg/m2 q3w (n = 76) 100 mg/m2 qw (n = 76) 150 mg/m2 qw (n = 74) 100 mg/m2 q3w (n = 74) grade 2 17 (22) 11 (14) 19 (26) 14 (19) grade 3 13 (17) 6 (8) 10 (14) 9 (12) grade 4 0 (0) 0 (0) 0 (0) 0 (0) grade 2 17 (22) 5 (7) 15 (20) 12 (16) grade 3 4 (5) 0 (0) 2 (3) 14 (19) grade 4 0 (0) 0 (0) 0 (0) 0 (0) Neuropatia, n (%) Fatigue, n (%) † Tossicità legate al trattamento riportate in ≥ 25% dei pazienti Gradishar W, et al. J Clin Oncol, 2009; 27(22): 3611-3619. qw or q3w nab-paclitaxel® vs q3w docetaxel: tossicità† nab-paclitaxel® Docetaxel 300 mg/m2 q3w (n = 76) 100 mg/m2 qw (n = 76) 150 mg/m2 qw (n = 74) 100 mg/m2 q3w (n = 74) grade 2 20 (26) 5 (7) 14 (19) 10 (14) grade 3 1 (1) 0 (0) 0 (0) 0 (0) grade 4 0 (0) 0 (0) 0 (0) 0 (0) grade 2 22 (29) 25 (33) 24 (32) 2 (3) grade 3 29 (39) 15 (20) 26 (35) 14 (19) grade 4 4 (5) 4 (5) 7 (9) 54 (75) 1.21 ± 1.00 1.51 ± 0.96 1.11 ± 0.63 0.38 ± 0.34 Artralgia Neutropenia Medio nadir ± SD, x 109/l † Tossicità legate al trattamento riportate in ≥ 25% dei pazienti Gradishar W, et al. J Clin Oncol, 2009; 27(22): 3611-3619. qw or q3w nab-paclitaxel® vs q3w docetaxel: grade 3 neuropatia migliorata più rapidamente con nab-paclitaxel • Neuropatia con simile frequenza in tutti i bracci di trattamento Proportion not improved 1.00 nab-paclitaxel® 300 mg/m2 q3w (A) nab-paclitaxel® 100 mg/m2 qw (B) nab-paclitaxel® 150 mg/m2 qw (C) Docetaxel 100 mg/m2 q3w (D) 0.75 • Tempo mediano al miglioramento – per nab-paclitaxel® 300 mg/m2, 100 mg/m2, 150 mg/m2 : 22, 22, 19 giorni 0.50 0.25 – vs docetaxel 37 giorni 0.00 0 10 20 30 40 50 60 70 80 90 100 Giorni Gradishar W, et al. J Clin Oncol, 2009; 27(22): 3611-3619. Conclusioni • nab-paclitaxel® ha dimostrato migliore tollerabilità ed efficacia rispetto a docetaxel • Tutti e tre i bracci di nab-paclitaxel® con più bassi tassi di neutropenia, neutropenia febbrile e fatigue • Il braccio più efficace di nab-paclitaxel® basato su PFS e ORR è risultato 150 mg/m2 qw • nab-paclitaxel® 150 mg/m2 qw è risultato superiore in maniera statisticamente significativa in termini di ORR e PFS rispetto a docetaxel • nab-paclitaxel® 100 mg/m2 qw è risultato associato con la minore tossicità Gradishar W, et al. J Clin Oncol, 2009; 27(22): 3611-3619. Ultimi Aggiornamenti - Dati di Overall Survival - Older patients with MBC Nab- Paclitaxel Versus Docetaxel for the First-line Treatment of Metastatic Breast Cancer (MBC): Final Overall Survival (OS) Analysis of a Randomized Phase 2 Trial ASCO Breast Symposium, September 8-10 , 2011, California Abstract # 275 Overall Survival Median OS (mo) AB-Pac 150mg/m2 qw (C) 33.8 AB-Pac 300mg/m2 q3w (A) 27.7 Taxotere 100mg/m2 q3w (D) 26.6 AB-Pac 100mg/m2 qw (B) 22.2 P HR Overall: 0.047 C vs B: 0.008 C vs D: - 0.575 0.688 • The 150 mg/m2 qw albumin-bound paclitaxel arm demonstrated: • A significantly longer median OS versus the 100 mg/m2 arm • A longer OS versus docetaxel, although this difference was not statistically significant • The OS benefit of the 150 mg/m2 arm was consistent among patient subgroups: • Age <65 vs ≥65 years • Visceral vs non-visceral disease • No. of visceral lesion sites <5 vs ≥5 • Pre-menopausal vs post-menopausal ASCO Breast Symposium, Abstract # 275 Overall Efficacy Analyses A significant (P= .047) treatment effect on OS was observed among the 4 tratment arms The OS benefit of 150 mg/mq qw nab-paclitaxel arm was consistent with results observed in investigator-assessed ORR and PFS ASCO Breast Symposium, Abstract # 275 Conclusion • Based on event-driven analysis of final OS, the nab-paclitaxel 150 mg/m2 qw 3/4 regimen provided the best clinical benefit for the forst-line treatment of patients with MBC • The median OS of 33.8 months compares favorably with historical values for taxane monotherapy for MBC • The OS benefit of the 150 mg/mq qw regimen in consistent with trends seen in investigator-assessed ORR and PFS • nab.-paclitaxel was generally well tolerated, and the safety profile is consistent with previous reports • These results support further eveluation of the 150 mg/mq qw dosing schedule of nab-paclitaxel in a randomized, phase 3 trial for the first-line treatment on MBC ASCO Breast Symposium, Abstract # 275 Weekly nab-paclitaxel is safe and effective in 65 years old patients with metastatic breast cancer: A post-hoc analysis Matti Aapro, Sergei Tjulandin, Paul Bhar, William Gradishar Purpose This post-hoc analysis of 2 studies (Gradishar W. 2005 and Gradishar W. 2009) investigated the safety and efficacy of weekly and every-3week (q3w) nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in older patients with metastatic breast cancer (MBC) compared with q3w solvent-based paclitaxel and docetaxel. Aapro M et al, The Breast 2011 Patient Population Among the total treatment population in the 2 studies: 114 (15%) were 65 years old (phase 2, n = 52; phase 3, n = 62) In the phase 2 study: 33 pt randomized to nab-paclitaxel 19 pt n= 9 n= 14 n= 10 300 mg/m2 q3w 100 mg/m2 weekly 150 mg/m2 weekly randomized to docetaxel In the phase 3 study: 30 pt 32 pt randomized to nab-paclitaxel randomized to paclitaxel Aapro M et al, The Breast 2011 Demographics/Baseline Characteristics Aapro M et al, The Breast 2011 Efficacy (1) In the phase 2 study ORR nab-paclitaxel 22% 300 mg/m2 q3w docetaxel 64% 60% 32% 100 mg/m2 weekly 150 mg/m2 weekly 100 mg/m2 q3w nab-paclitaxel 27% 260 mg/m2 q3w paclitaxel 19% 175 mg/m2 q3w In the phase 3 study ORR In the phase 2 study DCR nab-paclitaxel 56% 300 mg/m2 q3w docetaxel 86% 90% 79% 100 mg/m2 weekly 150 mg/m2 weekly 100 mg/m2 q3w nab-paclitaxel 53 % 260 mg/m2 q3w paclitaxel 41% 175 mg/m2 q3w In the phase 3 study DCR Aapro M et al, The Breast 2011 Efficacy (2) In the phase 2 study PFS median nab-paclitaxel docetaxel 13.8 9.2 18.9 8.5 300 mg/m2 q3w 100 mg/m2 weekly 150 mg/m2 weekly 100 mg/m2 q3w In the phase 3 study PFS median Aapro M et al, The Breast 2011 nab-paclitaxel 5.6 260 mg/m2 q3w paclitaxel 3.5 175 mg/m2 q3w Conclusion Weekly nab-paclitaxel was safe and more efficacious compared with the q3w schedule and with solvent-based taxanes in older patients with MBC. In particular, the 150 mg/m2 weekly for 3 weeks followed by 1 week of rest nab-paclitaxel resulted in 60% ORR and 21 months of median OS along with no SAEs and no deaths; thus, it may be the optimal dose of nab-paclitaxel therapy in patients 65 years old. These findings warrant further examination of weekly nabpaclitaxel in older patients with MBC. Aapro M et al, The Breast 2011 nab-Paclitaxel Ongoing Study in MBC Cooperative Group Trial with Biomarker Analysis Tumor biopsy on accessible tissue R A N D O M I Z E Paclitaxel 90 mg/m2 qw 3/4 nab-Paclitaxel 150 mg/m2 qw 3/4 Bevacizumab 10 mg/kg q2w Ixabepilone 16 mg/m2 qw 3/4 Serum for Caveolin-1 Tumor block for SPARC, tubulin mutations, Serial serum measurement of caveolin-1 Circulating Tumor Cells Serial measurement of CTC and CEC (CTC) and Circulating Endothelial Cells (CEC) CALGB and NCCTG, PI: Hope Rugo, Alvino Moreno; N=900